Patents by Inventor Purakkattle Biju

Purakkattle Biju has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7985748
    Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as ?2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the ?2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: July 26, 2011
    Assignees: Pharmacopeia Drug Discovery, Inc., Scheeing Corporation
    Inventors: Kevin D. McCormick, Christopher W. Boyce, Neng-Yang Shih, Robert G. Aslanian, Pietro Mangiaracina, Manuel de Lera Ruiz, Younong Yu, Purakkattle Biju, Chia-Yu Huang, Bo Liang, Ruiyan Liu, Rong-Qiang Liu, Lisa Guise-Zawacki
  • Publication number: 20100173823
    Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as ?2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the ?2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: March 12, 2010
    Publication date: July 8, 2010
    Inventors: Kevin D. McCormick, Christopher W. Boyce, Neng-Yang Shih, Robert G. Aslanian, Pietro Mangiaracina, Manuel de Lera Ruiz, Younong Yu, Purakkattle Biju, Chia-Yu Huang, Bo Liang, Ruiyan Liu, Rong-Qiang Liu, Lisa Guise-Zawacki
  • Patent number: 7638531
    Abstract: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: M is CH or N; U and W are each CH, or one of U and W is CH and the other is N; X is a bond, alkylene, —C(O)—, —C(N—OR5)—, —C(N—OR5)—CH(R6)—, —CH(R6)—C(N—OR5)—, —O—, —OCH2—, —CH2O— or —S(O)0-2—; Y is —O—, —(CH2)2—, —C(?O)—, —C(?NOR7)— or —SO0-2—; Z is a bond, optionally substituted alkylene or alkylene interrupted by a heteroatom or heterocyclic group; R1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, or benzimidazolyl or a derivative thereof; R2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods for treating an allergy-induced airway response, congestion, diabetes, obesity, an obesity-related disorder, metabolic syndrome and a cognition deficit disorder using said compounds, alone or in combinatio
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: December 29, 2009
    Assignee: Schering Corporation
    Inventors: Mwangi W. Mutahi, Robert G. Aslanian, Michael Y. Berlin, Christopher W. Boyce, Manuel de Lera Ruiz, Kevin D. McCormick, Daniel M. Solomon, Henry A. Vaccaro, Junying Zheng, Purakkattle Biju, Younong Yu, Wei Zhou, Xiaohong Zhu
  • Publication number: 20080090823
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
    Type: Application
    Filed: September 26, 2007
    Publication date: April 17, 2008
    Inventors: Purakkattle Biju, Arthur Taveras, J. Merritt, John Baldwin, Younong Yu, Junying Zheng, Jianhua Chao, Cynthia Aki, Jay Fine, Daniel Lundell, Tony Priestley, Angelo Reggiani
  • Publication number: 20070264230
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula IA.
    Type: Application
    Filed: January 9, 2007
    Publication date: November 15, 2007
    Inventors: Arthur Taveras, Jianhua Chao, Purakkattle Biju, Younong Yu, Jay Fine, William Hipkin, Cynthia Aki, J. Merritt, Ge Li, John Baldwin, Gaifa Lai, Minglang Wu, Evan Hecker
  • Publication number: 20070167435
    Abstract: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: M is CH or N; U and W are each CH, or one of U and W is CH and the other is N; X is a bond, alkylene, —C(O)—, —C(N—OR5)—, —C(N—OR5)—CH(R6)—, —CH(R6)—C(N—OR5)—, —O—, —OCH2—, —CH2O— or —S(O)0-2—; Y is —O—, —(CH2)2—, —C(?O)—, —C(?NOR7)— or —SO0-2—; Z is a bond, optionally substituted alkylene or alkylene interrupted by a heteroatom or heterocyclic group; R1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, or benzimidazolyl or a derivative thereof; R2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods for treating an allergy-induced airway response, congestion, diabetes, obesity, an obesity-related disorder, metabolic syndrome and a cognition deficit disorder using said compounds, alone or in combinat
    Type: Application
    Filed: December 19, 2006
    Publication date: July 19, 2007
    Inventors: Mwangi Mutahi, Robert Aslanian, Michael Berlin, Christopher Boyce, Manuel de Lera Ruiz, Kevin McCormick, Daniel Solomon, Henry Vaccaro, Junying Zheng, Purakkattle Biju, Younong Yu, Wei Zhou, Xiaohong Zhu
  • Publication number: 20070155756
    Abstract: Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).
    Type: Application
    Filed: February 14, 2007
    Publication date: July 5, 2007
    Inventors: Arthur Taveras, Motasim Billah, Daniel Lundell, William Kreutner, James Jakway, Jay Fine, Loretta Bober, Jianhua Chao, Purakkattle Biju, Younong Yu
  • Publication number: 20070093477
    Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as ?2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the ?2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.
    Type: Application
    Filed: August 23, 2006
    Publication date: April 26, 2007
    Inventors: Kevin McCormick, Christopher Boyce, Neng-Yang Shih, Robert Aslanian, Pietro Mangiaracina, Manuel de Lera Ruiz, Younong Yu, Purakkattle Biju, Chia-Yu Huang, Bo Liang, Ruiyan Liu, Rong-Qiang Liu, Lisa Guise-Zawacki
  • Publication number: 20070021494
    Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
    Type: Application
    Filed: August 8, 2006
    Publication date: January 25, 2007
    Inventors: Arthur Taveras, Cynthia Aki, Richard Bond, Jianping Chao, Michael Dwyer, Johan Ferreira, Jianhua Chao, Younong Yu, John Baldwin, Bernd Kaiser, Ge Li, J. Merritt, Purakkattle Biju, Kingsley Nelson, Laura Rokosz, Gaifa Lai, James Jakway, Minglang Wu, Evan Hecker, Daniel Lundell, Jay Fine
  • Publication number: 20070015731
    Abstract: Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof. The compounds are useful for the treatment of chemokine-mediated diseases such as COPD.
    Type: Application
    Filed: June 27, 2006
    Publication date: January 18, 2007
    Inventor: Purakkattle Biju
  • Publication number: 20070004682
    Abstract: Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof. X is N or N+O?, and Y is N or N+O?, provided that at least X or Y is N. The compounds are useful for the treatment of chemokine-mediated diseases such as COPD.
    Type: Application
    Filed: June 27, 2006
    Publication date: January 4, 2007
    Inventor: Purakkattle Biju
  • Publication number: 20060223864
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
    Type: Application
    Filed: December 16, 2004
    Publication date: October 5, 2006
    Inventors: Purakkattle Biju, Arthur Taveras, J. Merritt, John Baldwin, Younong Yu, Junying Zheng, Jianhua Chao, Cynthia Aki, Jay Fine, Daniel Lundell, Tony Priestley, Angelo Reggiani
  • Publication number: 20060025453
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
    Type: Application
    Filed: December 20, 2004
    Publication date: February 2, 2006
    Inventors: Arthur Taveras, J. Merritt, John Baldwin, Junying Zheng, Purakkattle Biju, Younong Yu, Jianhua Chao, Jay Fine, Daniel Lundell, Tony Priestley, Angelo Reggiani, Gaifa Lai, Minglang Wu